Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K5ER
|
|||
| Former ID |
DCL000633
|
|||
| Drug Name |
Rosiglitazone XR
|
|||
| Synonyms |
Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Approved | [1] | |
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [2] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23N3O7S
|
|||
| Canonical SMILES |
CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=CC(=O)O)C(=O)O
|
|||
| InChI |
1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
|
|||
| InChIKey |
SUFUKZSWUHZXAV-BTJKTKAUSA-N
|
|||
| CAS Number |
CAS 155141-29-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
534302, 7847662, 8616490, 11528774, 12014878, 14932160, 25624753, 39289979, 46386628, 48416528, 49681563, 50085993, 50962349, 57357987, 91615938, 92308261, 92713029, 103221370, 104021279, 104253660, 113854462, 124658939, 124757841, 124800524, 125164645, 126625071, 126656372, 126670703, 131300304, 135035653, 136340308, 144212684, 152100953, 162037971, 164194065, 164196622, 172080316, 175607691, 179323691, 184553565, 186011363, 187072521, 196111584, 210275109, 210280748, 223378748, 223660290, 223775226, 225231964, 226408885
|
|||
| ChEBI ID |
CHEBI:8892
|
|||
| ADReCS Drug ID | BADD_D01970 | |||
| SuperDrug ATC ID |
A10BG02
|
|||
| SuperDrug CAS ID |
cas=122320734
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Description | Rosiglitazone can be accumulated by Bacteroides thetaiotaomicron VPI-5482. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium animalis subsp.lactis BI-07
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Description | Rosiglitazone can be accumulated by Bifidobacterium animalis subsp.lactis BI-07. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Clostridium ramosum DSM 1402
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Description | Rosiglitazone can be accumulated by Clostridium ramosum DSM 1402. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lacticaseibacillus paracasei
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Description | Rosiglitazone can be accumulated by Lacticaseibacillus paracasei. | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 2 | Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131-46. | |||
| REF 3 | Bioaccumulation of therapeutic drugs by human gut bacteria. Nature. 2021 Sep;597(7877):533-538. | |||
| REF 4 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.